Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about Amyloid-β Clearance: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
The process by which amyloid-beta peptides are removed from the brain through enzymatic degradation (by neprilysin, insulin-degrading enzyme, BACE1 regulation), cellular phagocytosis by microglia, and transport across the blood-brain barrier via LRP1 and P-glycoprotein. Impaired clearance is a major contributor to amyloid plaque accumulation in Alzheimer's disease.
Ontology: GO:0097340 · MESH:D058031
No AI portrait yet
| Name | Amyloid Clearance |
| Key Genes/Proteins | TIM-3 |
| Linked Hypotheses | 4 hypotheses |
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| Disease Progression | modulates | process | 0.85 |
| disease progression | inhibits | disease | 0.70 |
| Source | Relation | Type | Str |
|---|---|---|---|
| Donanemab | promotes | drug | 0.95 |
| Donanemab | promotes | drug | 0.92 |
| Anti-Amyloid-beta Monoclonal Antibodies | modulates | drug | 0.90 |
| TREM2 | mediates | protein | 0.90 |
| TIM-3 | inhibits | protein | 0.85 |
| lecanemab/donanemab | promotes | drug | 0.85 |
| ASTROCYTES | regulates | cell_type | 0.80 |
| Glymphatic Clearance | involved_in | process | 0.80 |
| APOE3 | enhances | protein | 0.70 |
| TREM2 agonistic antibodies | enhances | drug | 0.70 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
neurodegeneration | 2026-04-16 | 0 hypotheses
neurodegeneration | 2026-04-08 | 0 hypotheses
neurodegeneration | 2026-04-02 | 4 hypotheses Top: 0.720
neurodegeneration | 2026-04-01 | 0 hypotheses
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| TREM2 KO amyloid pathology study | validation | Alzheimers Disease | 0.800 | 0.00 | Mouse (5xFAD/TREM2-/-) | completed | N/A |
| TREM2 KO amyloid pathology study | validation | Alzheimers Disease | 0.800 | 0.00 | Mouse (5xFAD/TREM2-/-) | completed | N/A |
| TREM2 KO amyloid pathology study | validation | Alzheimers Disease | 0.800 | 0.00 | Mouse (5xFAD/TREM2-/-) | completed | N/A |
| TREM2 KO amyloid pathology study | validation | Alzheimers Disease | 0.800 | 0.00 | Mouse (5xFAD/TREM2-/-) | completed | N/A |
| TREM2 KO amyloid pathology study | validation | Alzheimers Disease | 0.800 | 0.00 | Mouse (5xFAD/TREM2-/-) | completed | N/A |
| TREM2 KO amyloid pathology study | validation | Alzheimers Disease | 0.800 | 0.00 | Mouse (5xFAD/TREM2-/-) | completed | N/A |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clin [PMID:41324786] | Abushakra S, Doraiswamy PM, Hey JA, Tosu | CNS drugs | 2026 | 0 |
| Adverse childhood experiences and cardiometabolic risk factors in people with bi [PMID:40935250] | Turner A, Kuperberg M, McGovern H, Wrobe | J Affect Disord | 2026 | 0 |
| Indole-3-propionic acid links gut dysfunction to diabetic retinopathy: a biomark [PMID:41198173] | Prasad R, Adu-Rutledge Y, Ziani B, Floyd | Gut | 2026 | 0 |
| Amyloidosis of bridging veins is a pathologic feature of Alzheimer's disease. [PMID:41329157] | Smyth LCD, Verhaege D, Standen-Bloom E, | J Exp Med | 2026 | 0 |
| Integrative Multiomics Insights into the Genetic and Epigenetic Architecture of [PMID:41422555] | Mishra AK, Jain S | ACS Chem Neurosci | 2026 | 0 |
| A minimally invasive dried blood spot biomarker test for the detection of Alzhei [PMID:41491101] | Huber H, Montoliu-Gaya L, Brum WS, Vávra | Nat Med | 2026 | 0 |
| [Polypharmacy and nephrotoxicity]. [PMID:41535444] | Czock D, Ebinger K, Sommerer C | Inn Med (Heidelb) | 2026 | 0 |
| The association of Alzheimer's disease-related SNPs with mild cognitive impairme [PMID:41606232] | Xie Z, Tu W, Ye XF, Hua L, Zhang X et al | Sci Rep | 2026 | 0 |
| Association between sleep duration and fluid biomarkers of Alzheimer's disease: [PMID:41610733] | Young VM, Zeynoun J, Ruiz Laza A, Salard | Sleep Med Rev | 2026 | 0 |
| Long-term amyloid PET and MRI outcomes in a menopausal hormone therapy trial. [PMID:41618732] | Kantarci K, Kara F, Tosakulwong N, Fough | Alzheimers Dement | 2026 | 0 |
| Genetic risk factors of late-onset Alzheimer's disease: Insights into pathophysi [PMID:41622452] | Akkaoui J, Devadoss D, Rodriguez MD, Ari | Neural Regen Res | 2026 | 0 |
| Plasma ATN biomarkers across the alzheimer's disease continuum in a Chilean comm [PMID:41691306] | Orellana P, Henríquez F, Cabral-Miranda | Alzheimers Res Ther | 2026 | 0 |
| Neuro-renin-angiotensin-aldosterone system axis in alzheimer's disease: from mol [PMID:41706377] | Singh G, Maparu K, Aran KR | Metab Brain Dis | 2026 | 0 |
| Genetic Burden and <i>APOE</i> Methylation in a Korean Multi-Generational Alzhei [PMID:41745359] | Eom Je-Hyun; Cho Mu-Yeol; Kim Ji-Won; Ki | Journal of personalized medici | 2026 | 0 |
| Renin-angiotensin system blockade attenuates brain mitochondrial dysfunction, ox [PMID:41883437] | García Menéndez S, Inserra F, de Cavanag | World J Exp Med | 2026 | 0 |
| Genetic Architecture of Cognitive Resilience in Alzheimer's Disease: Mechanisms, [PMID:41893052] | Burdman Gabriel; Akkaoui Juliet; Colon N | Neurology international | 2026 | 0 |
| Association Between ACE (I/D) Polymorphism and Essential Hypertension (EH): An U [PMID:41899774] | Smallwood A, Akam E, Hunter DJ, Singh M, | Int J Environ Res Public Healt | 2026 | 0 |
| Posttraumatic stress disorder is associated with Alzheimer's disease-relevant mo [PMID:41960318] | Seijo MA, Yohannes PA, Rogers AL, Gonzal | Res Sq | 2026 | 0 |
| Genetic risk factors of late-onset Alzheimer's disease: Insights into pathophysi [PMID:41622452] | Akkaoui J, Devadoss D, Rodriguez MD, Ari | Neural regeneration research | 2026 | 0 |
| Genetic Architecture of Cognitive Resilience in Alzheimer's Disease: Mechanisms, [PMID:41893052] | ["Burdman G", "Akkaoui J", "Colon N", "P | Neurology international | 2026 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.82 · 2026-04-22
closed · Rounds: 4 · Score: 0.30 · 2026-04-21
closed · Rounds: 4 · Score: 0.70 · 2026-04-16
closed · Rounds: 4 · Score: 0.70 · 2026-04-12
closed · Rounds: 4 · Score: 0.92 · 2026-04-09
closed · Rounds: 4 · Score: 0.53 · 2026-04-06
Hypotheses and analyses mentioning Amyloid-β Clearance in their description or question text
Score: 0.622 · neurodegeneration · 2026-04-04
## Mechanistic Overview Microglial ACE Enhancement for Amyloid Clearance starts from the claim that modulating ACE withi
Score: 0.564 · Alzheimer's disease · 2026-04-17
## Mechanistic Overview Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscillations via glymph